NeoGenomics Company Profile (NASDAQ:NEO)

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics, Inc. (NASDAQ:NEO) posted its quarterly earnings data on Wednesday, April, 26th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.01 by $0.02. The firm had revenue of $61.68 million for the quarter, compared to the consensus estimate of $61.26 million. NeoGenomics had a negative net margin of 3.10% and a positive return on equity of 3.56%. The company's revenue for the quarter was up 3.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.03 earnings per share. View NeoGenomics' Earnings History.

NeoGenomics updated its FY17 earnings guidance on Wednesday, April, 26th. The company provided earnings per share guidance of $0.17-0.21 for the period, compared to the Thomson Reuters consensus estimate of $0.19. The company issued revenue guidance of $255-265 million, compared to the consensus revenue estimate of $264.60 million.NeoGenomics also updated its Q2 guidance to $0.03-0.04 EPS.

7 brokers have issued 12-month price objectives for NeoGenomics' stock. Their forecasts range from $10.00 to $12.00. On average, they anticipate NeoGenomics' stock price to reach $11.00 in the next year. View Analyst Ratings for NeoGenomics.

Here are some recent quotes from research analysts about NeoGenomics stock:

• 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (5/9/2017)
• 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $11 price target following last week's meeting with management. The company highlighted the strategic benefits of its tech-only offering, the Clarient acquisition, positive secular trends that are driving cancer diagnostics, and NEO's strong management team. The biggest takeaway, in our view, was that the Clarient integration continues to progress, which should drive further cost synergies as well as revenue synergies. We estimate that there is a $10-16M low-hanging revenue opportunity from targeting 100 Clarient accounts. We believe that the company will be able to unlock 25-40% of these and, thus, we are modeling $4-6M of revenue synergies ($2-3M in EBITDA contribution), with significant potential upside." (3/22/2017)

Some companies that are related to NeoGenomics include Abaxis (ABAX), Genomic Health (GHDX), Analogic (ALOG), BioTelemetry (BEAT), Heska Corp (HSKA), China Cord Blood Corp (CO), Natera (NTRA), Novadaq Technologies (NVDQ), Enzo Biochem (ENZ), InVitae Corp (NVTA), RadNet (RDNT), Miragen Therapeutics (MGEN), Alliance HealthCare Services (AIQ), Fluidigm (FLDM), Cytosorbents Corp (CTSO), VolitionRX Ltd (VNRX), Cancer Genetics (CGIX) and Biocept (BIOC).

NeoGenomics' management team includes the folowing people:

• Douglas M. VanOort, Chairman of the Board, Chief Executive Officer
• George A. Cardoza, Chief Financial Officer
• Robert J. Shovlin, Chief Operating Officer
• Steven C. Jones, Executive Vice President - Finance, Chief Compliance Officer, Director
• Edwin F. Weidig III, CPA, Principal Accounting Officer, Vice President - Finance
• Steven A. Ross, Chief Information Officer
• Steven G. Brodie Ph.d., Vice President - Operations
• Jennifer Balliet, Vice President - Human Resources
• Sally Agersborg M.D. Ph.D., Director of Hematopathology and Medical Director
• Maher Albitar M.D., Chief Medical Officer, Director - Research and Development

NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.41%), Artisan Partners Limited Partnership (3.12%), Next Century Growth Investors LLC (2.65%), RMB Capital Management LLC (2.15%), Janus Capital Management LLC (2.12%) and Driehaus Capital Management LLC (1.80%). Company insiders that own NeoGenomics stock include Alison L Hannah, Bruce K Crowther, George Cardoza, Lynn A Tetrault, Maher Albitar, Oort Douglas M Van, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.

NeoGenomics' stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Next Century Growth Investors LLC, Driehaus Capital Management LLC, Russell Investments Group Ltd., Summit Creek Advisors LLC, RMB Capital Management LLC, Millrace Asset Group Inc. and Artisan Partners Limited Partnership. Company insiders that have sold NeoGenomics stock in the last year include Maher Albitar and Steven G Brodie. View Insider Buying and Selling for NeoGenomics.

NeoGenomics' stock was acquired by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Gabelli Funds LLC, IronBridge Capital Management LP, Renaissance Technologies LLC, Emerald Advisers Inc. PA, Dimensional Fund Advisors LP, Cowen Prime Services LLC and Northpointe Capital LLC. Company insiders that have bought NeoGenomics stock in the last two years include Alison L Hannah, Bruce K Crowther, Lynn A Tetrault and Robert J Shovlin. View Insider Buying and Selling for NeoGenomics.

Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of NeoGenomics stock can currently be purchased for approximately $7.38.